Cardiometabolic & kidneyRandomised controlled trial
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
- Randomised controlled trial
- double-blind
- placebo-controlled
- multicentre (26 sites in Canada and Australia)
Authors' conclusion
The rate of serious cardiovascular events among participants receiving maintenance hemodialysis was lower with daily supplementation with n-3 fatty acids than with placebo.
Study context
- Population
- Adults receiving maintenance hemodialysis
- Participants
- 1,228 adults
- Comparison
- Fish oil vs corn-oil placebo
- Fish oiln = 610
- Placebon = 618reference
- Primary endpoint
- Serious CV events:
- Sudden and nonsudden cardiac death
- Fatal and nonfatal MI
- Peripheral vascular disease leading to amputation
- Fatal
- Nonfatal stroke
- Follow-up
- 3.5 years
Primary result
Serious CV events · 3.5 years
Hazard ratio
0.57
95% CI 0.47–0.70
P < 0.001
By group
Fish oil vs Placebo
HR 0.57 (95% CI 0.47–0.70); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Extended primary end point including noncardiac death | 0.77 (0.65–0.90) | |
| Cardiac death | 0.55 (0.40–0.75) | |
| Fatal and nonfatal MI | 0.56 (0.40–0.80) | |
| Peripheral vascular disease leading to amputation | 0.57 (0.38–0.86) | |
| Fatal and nonfatal stroke | 0.37 (0.18–0.76) | |
| First CV event or all-cause death | 0.73 (0.61–0.87) | |
| 0.20.5125Hazard ratio (log scale) |
Safety
Adverse events
- Adherence and adverse event incidence did not differ meaningfully between groups
Original publication
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. Published 7 November 2025. doi:10.1056/nejmoa2513032
Summarised from the published abstract; every number is checked against it